Based on our IHC results: (a) the expression of many metabolic enzymes showed intra- and intertumoral heterogeneity; (b) CPT1a expression is elevated in human glioma cases (our results confirm the potential importance of CPT1a expression in gliomas which was described in vitro by Wakamiya et al. [40]); and (c) GLS is overexpressed in IDH-mutant cases (the importance of glutamine metabolism was highlighted as special interest in glioma cases by others, as well [41]). The gene discussed is CPT1A; the disease is central nervous system cancer.